Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye Disease
NCT ID: NCT07297316
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2022-10-03
2024-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
R) DQS, L) REB
This is a paired-eye design study. Patients were randomly assigned to receive 3% diquafosol in the right eye and 2% rebamipide in the contralateral left eye, with the treatment assignment blinded to the examiner and patients.
3% diquafosol (right eye) and 2% rebamipide (left eye)
3% diquafosol was instilled in the right eye and 2% rebamipide in the left eye.
R) REB, L) DQS
This is a paired-eye design study. Patients were randomly assigned to receive 3% diquafosol in the left eye and 2% rebamipide in the contralateral right eye, with the treatment assignment blinded to the examiner and patients.
2% rebamipide (right eye) and 3% diquafosol (left eye)
2% rebamipide was instilled in the right eye and 3% diquafosol in the left eye.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3% diquafosol (right eye) and 2% rebamipide (left eye)
3% diquafosol was instilled in the right eye and 2% rebamipide in the left eye.
2% rebamipide (right eye) and 3% diquafosol (left eye)
2% rebamipide was instilled in the right eye and 3% diquafosol in the left eye.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* complaint of at least one dry eye symmptom and tear breakup time \< 7 seconds
Exclusion Criteria
* prescription history of systemic steroids or immunosuppressants
* prior ocular surgery within six months of enrollment
* treatment with diquafosol or rebamipide eye drops within 2 weeks of enrollment
* treatment with punctal plug within 1 month of enrollment
* intraocular pressure exceeding 25mmHg
* usage of contact lens during the study
* active ocular infection
* pregnancy or breast-feeding
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kukje Pharma
OTHER
Korea University Anam Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dong Hyun Kim
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Anam Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022AN0535
Identifier Type: -
Identifier Source: org_study_id